US IPO Week Ahead: A pair of biotechs plan to complete $200 million deals
Two biotechs, Bicara Therapeutics and Zenas BioPharma, plan to raise $200 million each in IPOs. Bicara's ficerafusp alfa targets EGFR and TGF-b for potent anti-tumor activity, while Zenas' obexelimab targets CD19 and FcγRIIb to treat autoimmune diseases. Both companies expect pivotal trial data in 2025.
Reference News
US IPO Week Ahead: A pair of biotechs plan to complete $200 million deals
Two biotechs, Bicara Therapeutics and Zenas BioPharma, plan to raise $200 million each in IPOs. Bicara's ficerafusp alfa targets EGFR and TGF-b for potent anti-tumor activity, while Zenas' obexelimab targets CD19 and FcγRIIb to treat autoimmune diseases. Both companies expect pivotal trial data in 2025.